

Network-Based Analysis of Rutin-Induced Gene Expression Changes in Human Senescent Stromal Cells

Lucia Novakova^{1*}, Petr Dolezal², Jana Horakova¹

¹Department of Pharmacognosy, Faculty of Pharmacy, Charles University, Prague, Czech Republic.

²Department of Plant Biotechnology, Faculty of Science, Masaryk University, Brno, Czech Republic.

*E-mail ✉ lucia.novakova@gmail.com

Received: 06 February 2024; Revised: 16 May 2024; Accepted: 19 May 2024

ABSTRACT

Rutin, a lipophilic flavonoid of natural origin, occurs in various vegetables, citrus fruits, and drinks. The purpose of this research is to examine the metabolic routes of rutin within human senescent stromal cells. Datasets were obtained from the Gene Expression Omnibus (GEO) repository and initially processed with GEO2R to detect significantly differentially expressed genes (DEGs). These significant DEGs underwent protein-protein interaction (PPI) network evaluation to pinpoint hub genes. Hub genes were further refined through directed PPI analysis to isolate the most crucial DEGs. Visualization of the data involved volcano plots, Uniform Manifold Approximation and Projection (UMAP) plots, and Venn diagrams. From an analysis of 9124 significant DEGs, 33 upregulated and 61 downregulated hub genes were identified. Subsequent directed PPI analysis highlighted IL1B, ICAM1, CCL2, EGF, CXCL8, PTGS2, CAMK2B, CCN2, VCAM1, ELN, CXCL12, BGN, and TLR4 as the key hub genes. The genes IL1B, CCL2, GNAO1, ICAM1, EGF, and CXCL8 were identified as primary regulators modulated by rutin, while PTGS2 and CAMK2B stood out as the genes most strongly regulated. These results suggest notable positive impacts of rutin on the performance of the treated cells. Such impacts support the prospects of rutin as a potential plant-based therapeutic agent. Additional studies are, however, essential to mitigate possible adverse effects.

Keywords: Gene, Hub, Human, Rutin

How to Cite This Article: Novakova L, Dolezal P, Horakova J. Network-Based Analysis of Rutin-Induced Gene Expression Changes in Human Senescent Stromal Cells. *Spec J Pharmacogn Phytochem Biotechnol.* 2024;4:256-63. <https://doi.org/10.51847/K2ybTj5Pym>

Introduction

Aging may be described as a gradual deterioration in organ performance coupled with diminished capacity to react to external cues. Efforts have been made by researchers to influence this process. Alterations in genomics and epigenetics [1], impaired mitochondrial activity [2], and various other disruptions can upset physiological balance, paving the way for age-linked pathologies. Cellular senescence represents a core feature of organ aging. It plays a role in the development of neurodegenerative disorders, cardiovascular conditions, and numerous cancers [3]. The contribution of senescent cells to a range of age-related pathologies is emphasized by approaches that target them to reduce many associated manifestations [4]. Senotherapeutics employ drugs to specifically act on senescent cells and are divided into two groups: senolytics, which trigger programmed cell death, and senomorphics, which inhibit the pro-inflammatory senescence-associated secretory phenotype (SASP) [5]. Senomorphics enable strategies to lessen the negative consequences of SASP without removing the cells entirely; this action mirrors that seen with compounds like aspirin, metformin, and resveratrol [6]. Various naturally occurring substances, particularly flavonoids and polyphenols, show strong antioxidant and anti-inflammatory properties capable of dampening inflammatory SASP. Kaempferol, for example, restrains SASP in human fibroblasts via lowered H₂O₂ generation, thus reducing the impact of senescence [7]. Rutin, a flavonoid derived from natural sources [8], is commonly present in vegetables and citrus fruits. Its ability to neutralize superoxide and peroxy radicals confers valuable antioxidant advantages [9]. Extracts of Ginkgo biloba containing rutin have

been noted to lower extracellular amyloid beta deposits in Alzheimer's disease [10]. The capacity of rutin to contribute to anti-aging mechanisms, including its possible senomorphic effects and SASP inhibition, continues to be explored. In work by Lee *et al.*, rutin was shown to improve skin elasticity and reduce wrinkles in skin fibroblasts, with increased expression of collagen I and A1 alongside reduced metalloproteinase levels [11].

Rutin is known to decrease the production of reactive oxygen species (ROS) triggered by UV exposure and to boost the function of superoxide dismutase (SOD), thioredoxin reductase, and glutathione peroxidase in plasma. Additionally, it helps maintain levels of vitamins C and E in skin fibroblasts exposed to UV radiation [12]. Pairing ascorbic acid with rutin further elevates catalase and SOD activities [13]. The precise molecular pathways through which rutin influences aging are not yet fully elucidated. Determining central proteins and genes associated with cellular senescence, together with exploring their interactions within rutin-involved metabolic processes, could aid in developing approaches to retard or avert aging. Tools from genomics and bioinformatics, including network analysis, offer effective means to reveal genes and proteins linked to aging that respond to rutin [14]. Human senescent stromal cells (PSC27) are derived from normal prostate tissue and consist mainly of fibroblasts with a minor fraction of non-fibrillar elements. These PSC27 cells can acquire SASP characteristics after exposure to genotoxic chemotherapy or radiation [15, 16]. This investigation sought to highlight essential genes participating in metabolic pathways influenced by rutin in the human senescent stromal cell line PSC27.

Materials and Methods

Data collection

To investigate the impact of rutin on normal human primary prostate stromal cells, the dataset GSE190279 was retrieved from the GEO database (<<https://www.ncbi.nlm.nih.gov/geo/geo2r/?acc=GSE190279>>). Samples GSM5719090-2 represent normal human primary prostate stromal cells exposed to 50 µg/mL bleomycin (BLEO) and 100 µM rutin to trigger senescence. Samples GSM5719087-9 serve as the control group, treated solely with 50 µg/mL BLEO.

Pre-evaluation analysis

The dataset was analysed using GEO2R to identify potential significant differentially expressed genes (DEGs). Significant DEGs were visualised through a volcano plot, while sample clustering was evaluated with a Uniform Manifold Approximation and Projection (UMAP) plot. The total count of significant DEGs was established using a Venn diagram.

PPI network analysis

Significant DEGs were separated into upregulated and downregulated groups and constructed into respective PPI networks using Cytoscape software version 3.7.2 [17]. Protein data were entered into the “protein query” section of the STRING database, and initial networks were built with undirected edges. Network topology was examined via the “Network Analyzer” tool in Cytoscape to detect central nodes. A threshold of mean + 2 standard deviations (SD) was used to select hub genes. Upregulated and downregulated hubs were then integrated into an action map incorporating directed edges for activation, inhibition, and expression using CluePedia version 1.5.7, applying the default kappa score [18]. The resulting directed PPI network was further examined to identify key hubs according to out-degree and in-degree centrality measures.

Statistical analysis

Differentially expressed genes were deemed significant at an adjusted p-value < 0.05. PPI networks were generated with a confidence score set to 0.2.

Results and Discussion

Volcano plot visualisation revealed numerous genes with significant dysregulation (**Figure 1**). Non-significant changes clustered centrally in the plot. UMAP analysis clearly distinguished treated samples from controls (**Figure 2**). The Venn diagram indicated a total of 9124 significant DEGs (**Figure 3**). An upregulated PPI network comprising 521 nodes and 7114 edges was generated, with a degree cutoff of 84 applied to select 33 upregulated hubs. The downregulated PPI network consisted of 1182 nodes and 26511 edges, and a degree cutoff of 122

identified 61 hubs. Both upregulated and downregulated DEGs were combined into a single directed PPI network (**Figure 4**). Node arrangements according to out-degree and in-degree values are presented in **Figures 5 and 6**. Previous research has explored the protective role of rutin against oxidative stress induced by a high-cholesterol diet. The capacity of rutin to modify gene expression in treated samples has been examined. Findings suggest that rutin largely restores gene expression levels altered by a high-cholesterol diet to near-control values [19].




Figure 1. Volcano plot displaying genes that are significantly upregulated and downregulated among the differentially expressed genes (DEGs); BLEOR and BLEO indicate the cell groups treated with bleomycin combined with rutin and bleomycin alone, respectively [1].




Figure 2. UMAP visualization of gene expression patterns in rutin-treated cells compared to control samples; BLEOR and BLEO indicate the cell groups treated with bleomycin combined with rutin and bleomycin alone, respectively; nbrs represents the count of neighboring points used to assess similarity [2].

GSE190279: DESeq2, Padj<0.05



Total: 18178

Figure 3. Venn diagram illustrating the overlap in gene expression profiles between rutin-treated cells and controls; BLEOR and BLEO indicate the cell groups treated with bleomycin combined with rutin and bleomycin alone, respectively [3].




Figure 4. Directed protein-protein interaction (PPI) network featuring upregulated and downregulated hub genes; green edges denote activation, red edges denote inhibition, and yellow edges denote expression [4].




Figure 5. Directed protein-protein interaction (PPI) network featuring upregulated and downregulated hub genes; node positions are determined by out-degree values, with larger nodes corresponding to higher out-degree [5].




Figure 6. Directed protein-protein interaction (PPI) network featuring upregulated and downregulated hub genes; node positions are determined by in-degree values, with larger nodes corresponding to higher in-degree [6].

Figure 1 reveals that rutin administration led to significant dysregulation in a large number of genes [1]. The UMAP projection in **Figure 2** illustrates distinct clustering, with rutin-treated samples clearly segregated from the control group during the clustering process [2]. According to the Venn diagram in **Figure 3**, a total of 9124 differentially expressed genes (DEGs) with statistical significance were linked to rutin exposure [3].

Key upregulated and downregulated DEGs were pinpointed using protein-protein interaction (PPI) network evaluation. Hub genes are often utilized to uncover the molecular pathways involved in pathologies and therapeutic actions [20, 21]. A directed PPI network encompassing both upregulated and downregulated hub genes was built to select the most central ones. **Figure 4** demonstrates that roughly 50% of these hubs form part of the largest connected component, linked through activation, inhibition, and expression interactions [4].

Within directed graphs, out-degree measures the quantity of edges departing from a node [22]. Accordingly, in this hub-focused PPI network, a node's out-degree reflects how many direct neighbors it activates, inhibits, or influences via expression. Greater out-degree implies stronger dominance over adjacent nodes, marking it as a more powerful hub. **Figure 5** identifies IL1B, ICAM1, CCL2, EGF, CXCL8, and GNAO1 as the leading hubs when ranked by out-degree [5]. These appear to serve as dominant regulators in the overall network.

In-degree, conversely, counts the edges arriving at a node in a directed PPI setup [23]. **Figure 6** highlights PTGS2, CAMK2B, CCN2, ICAM1, CXCL8, EGF, and TLR4 as possessing the highest in-degree scores [6]. This indicates that these seven genes are primarily targets of regulation from their direct neighbors.

A notable direct link between IL1B and PTGS2 is visible in **Figure 4**, with IL1B topping the out-degree ranking and PTGS2 leading in in-degree. ICAM1, though downregulated, is prominent due to elevated scores in both metrics. Elevated serum concentrations of intercellular adhesion molecule 1 (ICAM1) have been observed in individuals with diabetes, alongside increased renal expression in diabetic animal models relative to normal subjects. Research indicates that ICAM1 drives the onset of diabetes and associated nephropathy [24].

CXCL8, also downregulated, ranks highly in both out-degree and in-degree. Known as C-X-C motif chemokine ligand 8 (CXCL8), it aids in eliminating pathogens but is implicated in harmful events like fibrosis, organ damage, tumor development, and new blood vessel formation [25]. Epidermal growth factor (EGF), the third highlighted downregulated hub, similarly shows strong values in both degrees and is tied to cancer development, potentially supporting the growth of cancerous cells [26].

As a downregulated hub with the highest out-degree, IL1B (interleukin 1 beta) has been linked to worsening major depression and altering treatment outcomes [27].

GNAO1 (G protein subunit alpha o1), marked by substantial out-degree, contributes to gastric cancer advancement; its elevated expression accelerates tumor growth and lowers patient survival rates [28]. CCL2 (CC motif chemokine ligand 2), an upregulated hub with high out-degree, exhibits heightened levels in tumor sites and could drive the advancement of various solid cancers [29].

PTGS2 (prostaglandin-endoperoxide synthase 2, or cyclooxygenase 2) downregulation has been noted in epilepsy cases during valproate therapy, as reported by Rawat *C et al.* [30]. Rutin induces similar downregulation here. CAMK2B (calmodulin-dependent protein kinase 2b), another downregulated hub, is vital for memory formation and neural adaptability in rodents. Evidence points to roles for both CAMK2A and CAMK2B in numerous brain-related and mental health disorders [31].

TLR4 (toll-like receptor 4), a downregulated hub, orchestrates swift responses to infections, but improper control can spark excessive immunity tied to conditions such as acute lung damage, septic shock, persistent harmful inflammation, malignancy, and autoimmunity [32]. The remaining upregulated hub, CCN2 (cellular communication network factor 2, also called connective tissue growth factor or CTGF), governs extracellular matrix buildup, cell sticking, programmed cell death, and growth. It has been connected to regional scarring, stem cell decisions, vessel formation, cancer growth, and inflammatory processes [33].

Although rutin offers benefits against diabetes, cancer, and neural decline, it also carries potential unwanted effects. Additional studies seem essential to confirm its safety for clinical use.

From the PPI evaluation in this work, rutin influences the activity of multiple genes tied to various dysfunctions and disorders.

Conclusion

Overall, the major molecular shifts caused by rutin in normal human primary prostate stromal cells include reduced expression of ICAM1, EGF, CXCL8, IL1B, GNAO1, PTGS2, CAMK2B, and TLR4, together with increased expression of CCL2 and CCN2. The genes IL1B, CCL2, GNAO1, ICAM1, EGF, and CXCL8 were found to act as controlling elements, while ICAM1, EGF, CXCL8, PTGS2, CAMK2B, CCN2, and TLR4 were determined to be the main targets under regulation. Notably, ICAM1, EGF, and CXCL8 belong to both controlling and controlled groups. Existing studies underscore the positive impacts of rutin on cellular health, such as safeguarding against diabetes, kidney complications from diabetes, and tumor development. At the same time, potential risks have been highlighted.

Therefore, expanded research is advised to better understand and harness the beneficial properties of rutin.

Acknowledgments: None

Conflict of Interest: None

Financial Support: None

Ethics Statement: The study received approval from the Ethics Committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.SRC.REC.1403.005).

References

1. Kane AE, Sinclair DA. Epigenetic changes during aging and their reprogramming potential. *Crit Rev Biochem Mol Biol.* 2019;54(1):61-83.
2. Haas RH. Mitochondrial dysfunction in aging and diseases of aging. *Biology.* 2019;8(2):1-5.
3. Sun Y, Li Q, Kirkland JL. Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging. *Life Med.* 2022;1(2):103-19.
4. Xu Q, Fu Q, Li Z, Liu H, Wang Y, Lin X, et al. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. *Nat Metab.* 2021;3(12):1706-26.
5. Song S, Lam EWF, Tchkonina T, Kirkland JL, Sun Y. Senescent cells: emerging targets for human aging and age-related diseases. *Trends Biochem Sci.* 2020;45(7):578-92.
6. Zhang L, Pitcher LE, Prahalad V, Niedernhofer LJ, Robbins PD. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. *FEBS J.* 2023;290(5):1362-83.
7. Lim H, Park H, Kim HP. Effects of flavonoids on senescence-associated secretory phenotype formation from bleomycin-induced senescence in BJ fibroblasts. *Biochem Pharmacol.* 2015;96(4):337-48.
8. Negahdari R, Bohlouli S, Sharifi S, Maleki Dizaj S, Rahbar Saadat Y, Khezri K, et al. Therapeutic benefits of rutin and its nanoformulations. *Phytother Res.* 2021;35(4):1719-38.

9. Mauludin R, Müller RH, Keck CM. Development of an oral rutin nanocrystal formulation. *Int J Pharm.* 2009;370(1-2):202-9.
10. Morató X, Marquíé M, Tartari JP, Lafuente A, Abdelnour C, Alegret M, et al. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress. *Sci Rep.* 2023;13(1):1-12.
11. Choi SJ, Lee SN, Kim K, Joo DH, Shin S, Lee J, et al. Biological effects of rutin on skin aging. *Int J Mol Med.* 2016;38(1):357-63.
12. Gęgotek A, Rybałowska-Kawałko P, Skrzydlewska E. Rutin as a mediator of lipid metabolism and cellular signaling pathways interactions in fibroblasts altered by UVA and UVB radiation. *Oxid Med Cell Longev.* 2017;Article ID 4721352.
13. Gęgotek A, Ambrożewicz E, Jastrząb A, Jaročka-Karpowicz I, Skrzydlewska E. Rutin and ascorbic acid cooperation in antioxidant and antiapoptotic effect on human skin keratinocytes and fibroblasts exposed to UVA and UVB radiation. *Arch Dermatol Res.* 2019;311(3):203-19.
14. Johnson AA, Shokhirev MN, Wyss-Coray T, Lehallier B. Systematic review and analysis of human proteomics aging studies unveils a novel proteomic aging clock and identifies key processes that change with age. *Ageing Res Rev.* 2020;Article ID 101070.
15. Han L, Long Q, Li S, Xu Q, Zhang B, Dou X, et al. Senescent stromal cells promote cancer resistance through SIRT1 loss-potentiating overproduction of small extracellular vesicles. *Cancer Res.* 2020;80(16):3383-98.
16. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. *Nat Med.* 2012;18(9):1359-68.
17. Vafae R, Arjmand B, Hamzelo-Moghadam M, Razzaghi Z, Tavirani MR, Tavirani SR. Identification of targeted central genes (IGF1 and HMOX1) by indirect cold physical plasma in human melanocytes. *J Lasers Med Sci.* 2022;13:1-4.
18. Mansouri V, Tavirani MR, Tavirani SR. Gene screening of colorectal cancers via network analysis. *Gastroenterol Hepatol Bed Bench.* 2019;12(2):149-54.
19. Al-Rejaie SS, Aleisa AM, Sayed-Ahmed MM, Al-Shabanah OA, Abuhashish HM, Ahmed MM, et al. Protective effect of rutin on the antioxidant genes expression in hypercholesterolemic male Westar rat. *BMC Complement Altern Med.* 2013;13:1-9.
20. Rezaei Tavirani M, Rezaei Tavirani M, Mansouri V, Mahdavi SM, Valizadeh R, Rostami Nejad M, et al. Introducing crucial protein panel of gastric adenocarcinoma disease. *Gastroenterol Hepatol Bed Bench.* 2017;10(1):21-8.
21. Rezaei Tavirani M, Rezaei Tavirani S, Mansouri V, Rostami Nejad M, Rezaei Tavirani M. Protein-protein interaction network analysis for a biomarker panel related to human esophageal adenocarcinoma. *Asian Pac J Cancer Prev.* 2017;18(12):3357-63.
22. Mishra V, Jain P, Khanna S. Using of cytoscape build large scale interface bionetwork and analysis topological distinctiveness of PPIs of Mycobacterium tuberculosis H37Rv. *Madridge J Mol Biol.* 2019;1(1):4-13.
23. Bánky D, Iván G, Grolmusz V. Equal opportunity for low-degree network nodes: a PageRank-based method for protein target identification in metabolic graphs. *PLoS One.* 2013;8(1):1-7.
24. Gu HF, Ma J, Gu KT, Brismar K. Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy. *Front Endocrinol.* 2013;3:1-7.
25. Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. *Theranostics.* 2017;7(6):1543-88.
26. Klijn J, Berns P, Schmitz P, Foekens J. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. *Endocr Rev.* 1992;13(1):3-17.
27. Baune BT, Dannlowski U, Domschke K, Janssen DG, Jordan MA, Ohrmann P, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. *Biol Psychiatry.* 2010;67(6):543-49.
28. Liu Z, Zhang J, Wu L, Liu J, Zhang M. Overexpression of GNAO1 correlates with poor prognosis in patients with gastric cancer and plays a role in gastric cancer cell proliferation and apoptosis. *Int J Mol Med.* 2014;33(3):589-96.

29. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. *Cytokine Growth Factor Rev.* 2010;21(1):41-8.
30. Rawat C, Kutum R, Kukal S, Srivastava A, Dahiya UR, Kushwaha S, et al. Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy. *Sci Rep.* 2020;10(1):1-14.
31. Küry S, van Woerden GM, Besnard T, Onori MP, Latypova X, Towne MC, et al. De novo mutations in protein kinase genes CAMK2A and CAMK2B cause intellectual disability. *Am J Hum Genet.* 2017;101(5):768-88.
32. Heine H, Zamyatina A. Therapeutic targeting of TLR4 for inflammation, infection, and cancer: a perspective for disaccharide lipid A mimetics. *Pharmaceuticals.* 2022;16(1):1-26.
33. Zaykov V, Chaqour B. The CCN2/CTGF interactome: an approach to understanding the versatility of CCN2/CTGF molecular activities. *J Cell Commun Signal.* 2021;15(4):567-80.